Skip to content

US · IONS · BIOTECHNOLOGY

Ionis Pharmaceuticals, Inc. (IONS) intrinsic value and stock valuation

$26.58as of 2026-11-21 · Mkt cap 9.01B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ionis Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values IONS with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from IONS’s statements →

Ionis Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carlsbad, CA 92010 ionis.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$944M+5.3% 5y CAGRd
20112025
Net income
-$-381M
20112025
Free cash flow
-$-320.03M
20112025
Total equity
$489.1M-8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$944M$705.1M$787.7M$587.4M$810.5M
Operating income-$-382M-$-475.08M-$-353.73M-$-410.19M-$-30.19M
Net income-$-381M-$-453.9M-$-366.29M-$-269.72M-$-28.6M
EPSd-$-2.38M-$-3.04M-$-2.56M-$-1.9M-$-202.81K
Operating cash flow-$-268.58M-$-500.95M-$-307.51M-$-274.37M$30.8M
Capital expenditure-$-51.44M-$-45.28M-$-28.01M-$-20.1M-$-17.9M
Free cash flow-$-320.03M-$-546.23M-$-335.52M-$-294.47M$12.9M
Total assets$3.52B$3B$2.99B$2.53B$2.61B
Total debt$2.61B$1.42B$1.45B$1.37B$1.25B
Net debt$2.24B$1.17B$1.05B$1.09B$381.9M
Total equity$489.1M$588.4M$386.7M$572.9M$771.7M
Cash and short-term investments$2.68B$2.3B$2.33B$2B$2.13B
Income statement
20252024202320222021
Revenue$944M$705.1M$787.7M$587.4M$810.5M
Cost of revenue$16M$11.2M$9.13M$14.1M$10.8M
Gross profit$928M$693.9M$778.5M$573.3M$799.6M
Research and development expenses$916M$901.5M$899.6M$833M$643M
Selling, general and administrative expenses$394M$267.5M$232.6M$150.3M$170.9M
Other expenses$0.00-$-30K$20K$150K$15.9M
Operating expenses$1.31B$1.17B$1.13B$983.4M$829.8M
Cost and expenses$1.33B$1.18B$1.14B$997.6M$840.6M
Interest income$97.8M$107M$89M$25.3M$10M
Interest expense$90.5M$90.5M$81.5M$8.12M$9.35M
Depreciation and amortization$20.3M$22M$22.5M$22.1M$19.6M
Ebitda-$-286.75M-$-353.72M-$-235.87M-$-227.76M-$-5.19M
Operating income-$-382M-$-475.08M-$-353.73M-$-410.19M-$-30.19M
Total other income/expenses, net$2M$15M$19.8M$152.2M$1.04M
Income before tax-$-380M-$-460.07M-$-333.96M-$-257.99M-$-29.15M
Income tax expense$1M-$-6.17M$32.3M$11.7M-$-550K
Net income-$-381M-$-453.9M-$-366.29M-$-269.72M-$-28.6M
Weighted average shares outstanding$160M$149.5M$143M$141.9M$141M
Weighted average diluted shares outstanding$160M$149.5M$143.2M$141.9M$141M
Balance sheet
20252024202320222021
Cash and short-term investments$2.68B$2.3B$2.33B$2B$2.13B
Net receivables$66M$92.2M$97.8M$25.5M$61.9M
Inventory$10.1M$12.5M$7.44M$22M$24.8M
Total current assets$2.99B$2.62B$2.64B$2.2B$2.35B
Property, plant and equipment, net$362M$256.1M$242.9M$255.8M$196M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$29M
Long-term investments$52.2M$41M$43M$40.4M$32.3M
Total non-current assets$533.2M$383.4M$348.2M$331.2M$266.6M
Total assets$3.52B$3B$2.99B$2.53B$2.61B
Accounts payable$28.1M$43M$26M$17.9M$11.9M
Short-term debt$453.2M$9.28M$53.2M$7.54M$3.53M
Deferred revenue$73.8M$79M$151.1M$90.6M$97.7M
Total current liabilities$781.6M$309.3M$448.1M$311.6M$240.6M
Long-term debt$2.16B$1.41B$1.4B$1.36B$1.25B
Deferred revenue, non-current$92M$156.5M$241.2M$287.8M$351.9M
Total non-current liabilities$2.25B$2.11B$2.16B$1.65B$1.6B
Capital lease obligations$262.4M$161.8M$170.9M$178.9M$19.4M
Total liabilities$3.03B$2.42B$2.6B$1.96B$1.84B
Common stock$160K$160K$140K$140K$140K
Retained earnings-$-2.63B-$-2.25B-$-1.8B-$-1.43B-$-1.16B
Accumulated other comprehensive income (loss)-$-25.28M-$-30.81M-$-32.65M-$-57.48M-$-32.67M
Total equity$489.1M$588.4M$386.7M$572.9M$771.7M
Total investments$2.36B$2.1B$1.98B$1.76B$1.3B
Total debt$2.61B$1.42B$1.45B$1.37B$1.25B
Net debt$2.24B$1.17B$1.05B$1.09B$381.9M
Cash flow statement
20252024202320222021
Net income-$-381.39M-$-453.9M-$-366.29M-$-269.72M-$-28.6M
Depreciation and amortization$22.7M$19.7M$22.5M$22.1M$19.6M
Stock-based compensation$133.9M$130.2M$105.8M$100.3M$120.7M
Change in working capital-$-51.22M-$-209.39M-$-77.26M$7.57M-$-113.82M
Accounts receivable$26.1M$5.59M-$-72.06M$36.4M$5.05M
Inventory-$-13.67M-$-5.07M-$-6.39M$2.77M-$-2.84M
Accounts payable-$-15.36M$16M$8.12M$1.09M-$-6M
Net cash provided by operating activities-$-268.58M-$-500.95M-$-307.51M-$-274.37M$30.8M
Investments in property, plant and equipment-$-51.44M-$-45.28M-$-23.8M-$-20.1M-$-17.9M
Acquisitions, net$0.00$0.00$20K$254.1M$5.95M
Net cash used for investing activities-$-277.78M-$-134.03M-$-214.13M-$-262.64M$194.9M
Common stock issued$192.6M$522.7M$49.4M$6.37M$85.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$675.8M$478.1M$644.1M-$-55.3M$245.9M
Net change in cash$130.2M-$-157.19M$122.8M-$-592.72M$471.5M
Cash at end of period$372.3M$242.1M$399.3M$276.5M$869.2M
Operating cash flow-$-268.58M-$-500.95M-$-307.51M-$-274.37M$30.8M
Capital expenditure-$-51.44M-$-45.28M-$-28.01M-$-20.1M-$-17.9M
Free cash flow-$-320.03M-$-546.23M-$-335.52M-$-294.47M$12.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ionis Pharmaceuticals, Inc.

        Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.

        CEO
        Brett Monia
        Employees
        1.4K
        Beta
        0.36

        Explore

        Frequently asked questions

        What is the intrinsic value of Ionis Pharmaceuticals, Inc. (IONS)?

        Ionis Pharmaceuticals, Inc. (IONS) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IONS undervalued?

        IONS trades at a price of $26.58 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.